May 13, 2022

Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down

Shares of Roche RHHBY were down 9.1% after it announced disappointing results from the phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer (NSCLC).

This post was originally published on this site

Sign Up To Get FREE News, Tips and Offers!

X